Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats

Duncan J. Campbell, Frank Anastasopoulos, Ann-Maree Duncan, Gail M. James, Athena Kladis and Todd A. Briscoe
Journal of Pharmacology and Experimental Therapeutics November 1998, 287 (2) 567-577;
Duncan J. Campbell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Anastasopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann-Maree Duncan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gail M. James
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athena Kladis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd A. Briscoe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The combination of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) inhibition is a candidate therapy for hypertension and cardiac failure. Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on the levels of these peptides. We administered the NEP inhibitor ecadotril (0, 0.1, 1, 10, 100 mg/kg per day), either alone or together with the ACE inhibitor perindopril (0.2 mg/kg per day), to rats by 12 hourly gavage for 7 days. Ecadotril produced diuresis, natriuresis, increased urine cyclic guanosine monophosphate and BK-(1–9) levels, increased Ang II and Ang I levels in plasma, and increased Ang I levels in heart. Perindopril reduced Ang II levels in kidney, and increased BK-(1–9) levels in blood, kidney and aorta. Combined NEP/ACE inhibition produced the summation of these effects of separate NEP and ACE inhibition. In addition, perindopril potentiated the ecadotril-mediated diuresis, natriuresis and decrease in urine BK-(1–7)/BK-(1–9) ratio, which is an index of BK-(1–9) metabolism. Moreover, combined NEP/ACE inhibition increased Ang II levels in plasma and lung. These data indicate that summation of the effects of separate NEP and ACE inhibition provides the basis for the therapeutic efficacy of their combination. Whereas potentiation by perindopril of the diuretic and natriuretic effects of ecadotril may contribute to the therapeutic effects, increased Ang II levels in plasma and lung may compromise the therapeutic effects of combined NEP/ACE inhibition.

Footnotes

  • Send reprint requests to: Dr. D. J. Campbell, St. Vincent’s Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia.

  • 1 This study was supported by grants from the National Health and Medical Research Council of Australia and from Bayer.AG, Wuppertal, Germany.

  • Abbreviations:
    ACE
    angiotensin converting enzyme
    Ang I
    angiotensin I
    Ang II
    angiotensin II
    ANOVA
    analysis of variance
    ANP
    atrial natriuretic peptide
    B2 receptor
    type 2 bradykinin receptor
    BK-(1–7)
    bradykinin-(1–7)
    BK-(1–8)
    bradykinin-(1–8)
    BK-(1–9)
    bradykinin-(1–9)
    ecadotril
    N-(S)-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-glycine benzylester
    EDTA
    ethylenediaminetetra-acetate
    GMP
    guanosine monophosphate
    GTC/TFA
    4 M guanidine thiocyanate, 1% trifluoroacetic acid
    HPLC
    high-performance liquid chromatography
    NEP
    neutral endopeptidase 24.11
    RB104
    2-[(3-iodo-4-hydroxy)phenylmethyl]-4-N-[3-(hydroxyamino-3-oxo-1-phenylmethyl)propyl]amino-4-oxobutanoic acid
    RIA
    radioimmunoassay
    SHR
    spontaneously hypertensive rat
    Tris
    tris-(hydroxymethyl)aminomethane
    • Received February 24, 1998.
    • Accepted June 9, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 2
1 Nov 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats

Duncan J. Campbell, Frank Anastasopoulos, Ann-Maree Duncan, Gail M. James, Athena Kladis and Todd A. Briscoe
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 567-577;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats

Duncan J. Campbell, Frank Anastasopoulos, Ann-Maree Duncan, Gail M. James, Athena Kladis and Todd A. Briscoe
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 567-577;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
  • Discriminative Stimulus Effects of Zolpidem in Squirrel Monkeys: Comparison with Conventional Benzodiazepines and Sedative-Hypnotics
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics